Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01151410 · ClinicalTrials.gov registry record · Phase 3
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Phase 3 study of Hypertension, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 208
- Enrollment target
- 20
- Study locations
NCT01151410 is a Phase 3 study of Hypertension that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 208 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT01151410, a Phase 3 study of Hypertension, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 208 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with hypertension (msSBP ≥ 95th percentile for age, gender and height, at baseline in study CSPP100A2365). Patients will be randomized to receive either aliskiren or enalapril. Weight-group based doses of aliskiren or enalapril will be administered once daily and children will receive study medication in a double-blind manner. This study is being conducted to support monotherapy registration of aliskiren for the treatment of hypertension in pediatric patients 6-17 years of age (age at baseline in Study CSPP100A2365).
Conditions Studied
Interventions
- DRUG Aliskiren
- DRUG Enalapril
Study Locations (20)
Mississippi
- Novartis Investigative Site - Hattiesburg
- Novartis Investigative Site - Jackson
Ohio
- Novartis Investigative Site - Columbus
- Novartis Investigative Site - Toledo
Oregon
- Novartis Investigative Site - Portland
- Novartis Investigative Site - Portland
Hungary
- Novartis Investigative Site - Nyíregyháza
- Novartis Investigative Site - Szeged
Alabama
- Novartis Investigative Site - Birmingham
Arkansas
- Novartis Investigative Site - Little Rock
California
- Novartis Investigative Site - Los Angeles
Georgia
- Novartis Investigative Site - Dalton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2010-08 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01151410
The ClinicalTrials.gov registry entry for NCT01151410 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (94% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Aliskiren is the first listed.
NCT01151410 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Mississippi, Ohio, Oregon.
Frequently Asked Questions
What is clinical trial NCT01151410 about?
NCT01151410 is a clinical study titled "An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age". The purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with hypertension (msSBP ≥ 95th percentile for age, gender and height, at bas...
What is the current status of trial NCT01151410?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 208 participants. The study started on 2010-08. Estimated completion is 2015-08.
What conditions does trial NCT01151410 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT01151410?
The interventions under investigation include: Aliskiren (DRUG), Enalapril (DRUG).
Who is sponsoring clinical trial NCT01151410?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01151410 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.